USPTO Examiner XIAO YAN - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18759723ANTIBODY-DRUG CONJUGATES AND USES THEREOFJune 2024December 2024Allow610YesNo
18749504DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITYJune 2024January 2025Allow710YesNo
18749522DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITYJune 2024March 2025Allow910YesNo
18393153METHODS FOR MODULATING AN IMMUNE RESPONSEDecember 2023December 2024Abandon1211NoNo
18227057METHODS FOR MODULATING AN IMMUNE RESPONSEJuly 2023January 2024Allow621NoNo
18143978DOSING PARAMETERS FOR CD47 TARGETING THERAPIES TO HEMATOLOGIC MALIGNANCIESMay 2023November 2023Allow610YesNo
18177729ANTI-CD39 ANTIBODIES AND USE THEREOFMarch 2023March 2024Allow1311YesNo
18154998SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOFJanuary 2023December 2023Allow1111YesNo
18069712ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASESDecember 2022August 2024Allow1910YesNo
18048644FACTOR XI A2 DOMAIN-BINDING ANTIBODIES AND METHODS OF USE THEREOFOctober 2022January 2025Allow2711YesNo
18047243COMBINATION THERAPY USING A LIV1-ADC AND A CHEMOTHERAPEUTICOctober 2022April 2025Abandon3001NoNo
17961001METHODS FOR MODULATING AN IMMUNE RESPONSEOctober 2022June 2023Allow811NoNo
17938317TCR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATINGOctober 2022December 2023Abandon1510YesNo
17933193RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOFSeptember 2022July 2025Allow3311YesNo
17818838COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENTAugust 2022June 2025Abandon3511NoNo
17852419NKp46 BINDING AGENTSJune 2022March 2025Allow3301YesNo
17834709COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITORJune 2022January 2023Allow710NoNo
17805121MULTISPECIFIC ANTAGONISTSJune 2022July 2023Abandon1310YesNo
17752631METHODS OF CONJUGATING AN AGENT TO A THIOL MOIETY IN A PROTEIN THAT CONTAINS AT LEAST ONE TRISULFIDE BONDMay 2022June 2025Abandon3701NoNo
17736874MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLSMay 2022June 2023Allow1330NoNo
17736847MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLSMay 2022June 2023Allow1330YesNo
17736222TREATMENT USING CHIMERIC RECEPTOR T CELLS INCORPORATING OPTIMIZED POLYFUNCTIONAL T CELLSMay 2022February 2025Abandon3401NoNo
17735880PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODYMay 2022March 2025Allow3411YesNo
17733260NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERApril 2022January 2023Allow910NoNo
17728671CANCER VACCINES TARGETING LEMD1 AND USES THEREOFApril 2022February 2025Allow3411YesNo
17728704Cancer Vaccines Targeting PRAME and Uses ThereofApril 2022April 2025Allow3511YesNo
17725932IDENTIFICATION OF IMMUNOLOGICALLY PROTECTIVE NEO-EPITOPES FOR THE TREATMENT OF CANCERSApril 2022March 2025Allow3510YesNo
17718822METHODS OF TREATING INFLAMMATORY DISORDERS WITH MULTIVALENT FC COMPOUNDSApril 2022February 2025Allow3410NoNo
17709324COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITORMarch 2022October 2023Abandon1830YesNo
17707838ENDOSIALIN-BINDING ANTIBODYMarch 2022December 2024Abandon3301NoNo
17586177COMBINATION OF ANTIBODY-DRUG CONJUGATE AND IMMUNE CHECKPOINT INHIBITORJanuary 2022February 2025Allow3611NoNo
17648792HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOFJanuary 2022March 2025Abandon3810NoNo
17582160CHIMERIC PROTEINS FOR TARGETING dsRNAJanuary 2022November 2024Abandon3401NoNo
17575616METHODS OF CANCER TREATMENT USING ACTIVATED T CELLSJanuary 2022January 2025Allow3710YesNo
17570917METHODS AND COMPOSITIONS FOR T CELL THERAPYJanuary 2022April 2025Allow3921YesNo
17567923EARLY APOPTOTIC CELLS FOR USE TREATING SEPSISJanuary 2022January 2025Allow3610YesNo
17563162Pharmaceutical Composition for Treating TumorDecember 2021September 2022Allow931YesNo
17559824CANCER VACCINES TARGETING MUC16 AND USES THEREOFDecember 2021December 2024Allow3611NoNo
17558430BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMADecember 2021July 2023Allow1931YesNo
17553624ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPYDecember 2021January 2025Allow3711YesNo
17540672COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLSDecember 2021October 2024Abandon3501NoNo
17532332CANCER ANTIGEN TARGETS AND USES THEREOFNovember 2021February 2025Allow3911YesNo
17529566METHOD FOR OBTAINING GLOBALLY ACTIVATED MONOCYTESNovember 2021March 2025Allow4011NoNo
17527835MOLECULAR SIGNATURE OF CANCERNovember 2021May 2025Allow4221YesNo
17508474METHODS TO PRESERVE TUMOR-STROMAL INTERACTIONS IN CULTURE AND THERAPEUTIC PREDICTIVE APPLICATIONS THEREOFOctober 2021March 2025Allow4131YesNo
17500874POOLED NK CELLS FROM UMBILICAL CORD BLOOD ASSOCIATED WITH ANTIBODIES AND THEIR USES FOR THE TREATMENT OF DISEASEOctober 2021December 2024Allow3810YesNo
17492219NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCEROctober 2021December 2021Allow200NoNo
17491742NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCEROctober 2021April 2024Allow3011NoNo
17484703NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERSeptember 2021November 2021Allow200NoNo
17484568NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERSeptember 2021November 2024Abandon3821YesNo
17482708NOVEL BISPECIFIC POLYPEPTIDES AGAINST CD137September 2021August 2024Allow3512YesNo
17479142CANCER VACCINES TARGETING BORIS AND USES THEREOFSeptember 2021August 2024Allow3421YesNo
17471803METHODS AND MATERIALS FOR ASSESSING IMMUNE SYSTEM PROFILESSeptember 2021August 2024Allow3510NoNo
17469488ANTI-CD40 ANTIBODIES AND USES THEREOFSeptember 2021July 2024Allow3421YesNo
17467728CANCER VACCINES TARGETING MESOTHELIN AND USES THEREOFSeptember 2021January 2024Allow2811YesNo
17468265Dosing Parameters for CD47 Targeting Therapies to Hematologic MalignanciesSeptember 2021December 2024Allow3931YesNo
17459460METHODS OF TREATING CERVICAL CANCERAugust 2021October 2024Abandon3810NoNo
17430171METHODS OF TREATMENT AND RELATED COMPOSITIONSAugust 2021October 2022Allow1410YesNo
17397217ANTIBODY-DRUG CONJUGATES AND USES THEREOFAugust 2021December 2023Abandon2901NoNo
17395366COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITORAugust 2021September 2023Abandon2500NoNo
17444511TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTSAugust 2021July 2024Abandon3601NoNo
17383855IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERJuly 2021January 2024Allow2911NoNo
17383892NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERJuly 2021January 2024Allow3011NoNo
17383076Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use ThereofJuly 2021April 2024Allow3321YesNo
17381858METHODS FOR MODULATING AN IMMUNE RESPONSEJuly 2021December 2023Allow2911YesNo
17375793HER-2 Binding AntibodiesJuly 2021June 2024Allow3521YesNo
17366512Inhibitory Immune Receptor Inhibition Methods and CompositionsJuly 2021March 2024Abandon3311NoNo
17358676IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERJune 2021January 2024Allow3011NoNo
17357410ANTI-TUMOR T CELL IMMUNITY INDUCED BY HIGH DOSE RADIATIONJune 2021July 2024Abandon3710NoNo
17351963COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC BIOLOGICS FOR TREATMENT OF DISEASEJune 2021April 2022Allow1020YesNo
17350963MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLSJune 2021March 2022Allow910NoNo
17351014ANTIBODIES SPECIFIC TO MUC18June 2021March 2025Allow4511YesNo
17336588THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)June 2021March 2024Abandon3310NoNo
17328364DISEASE-ASSOCIATED ANTIGENS AND METHODS OF USE THEREOFMay 2021September 2023Allow2811YesNo
17328103ANTI-HER2 COMBINATIONS FOR TREATING TUMORSMay 2021November 2023Abandon3001NoNo
17328465IDENTIFICATION, SELECTION AND USE OF HIGH CURATIVE POTENTIAL T CELL EPITOPESMay 2021September 2023Abandon2701NoNo
17328116ANTI-HER2 COMBINATIONS FOR TREATING TUMORSMay 2021April 2024Abandon3511NoNo
17327116NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERMay 2021August 2023Allow2711NoNo
17324148Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminaseMay 2021October 2024Allow4131YesNo
17320782IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERMay 2021September 2023Allow2811NoNo
17317864ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPYMay 2021October 2021Allow610NoNo
17302687MANF as a Regulator of Immune System FunctionMay 2021July 2024Abandon3921NoNo
17291794SYSTEMS AND METHODS FOR TARGETING CANCER CELLSMay 2021June 2025Allow4921YesNo
17290078STABLE PREPARATION COMPRISING ANTI-PCSK9 ANTIBODYApril 2021June 2025Abandon4921YesNo
17238943NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERApril 2021August 2023Allow2711NoNo
17236709IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGEApril 2021February 2024Abandon3410NoNo
17286748Targeting CLPTM1L for Treatment and Prevention of CancerApril 2021June 2024Allow3810YesNo
17226199CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITORApril 2021October 2023Allow3010YesNo
17221854COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENTApril 2021March 2024Abandon3621NoNo
17220799DEVELOPMENT OF DUAL WHOLE CELL-BASED VACCINE AGAINST PANCREATIC CANCERApril 2021April 2024Allow3720NoNo
17204846METHODS OF CANCER TREATMENT USING ACTIVATED T CELLSMarch 2021September 2021Allow601YesNo
17249762HISTOCHEMICAL AND CYTOCHEMICAL METHODS FOR DETECTING NTRK FUSION PROTEINSMarch 2021April 2025Allow4931YesNo
17193933CELL-PENETRATING ANTI-DNA ANTIBODIES AND USES THEREOF INHIBIT DNA REPAIRMarch 2021May 2024Abandon3821NoNo
17193795COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITORMarch 2021May 2023Abandon2601NoNo
17187468COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITORFebruary 2021July 2021Allow410YesNo
17180064METHODS FOR MODULATING AN IMMUNE RESPONSEFebruary 2021June 2021Allow410YesNo
17267164COMPLEMENT FACTOR H AND Fc BINDING DOMAIN FUSION PROTEINSFebruary 2021March 2025Abandon4911NoNo
17161253NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCERJanuary 2021April 2021Allow200NoNo
17157126ENDOPLASMIC RETICULUM STRESS AS A PREDICTIVE TOOL IN CANCER THERAPY AND A COMBINATION THERAPY FOR THE TREATMENT OF CANCERJanuary 2021July 2023Allow2911YesNo
17153345METHODS AND USES FOR TREATING CANCERJanuary 2021July 2023Allow3031YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner XIAO, YAN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.4%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
29
Allowed After Appeal Filing
8
(27.6%)
Not Allowed After Appeal Filing
21
(72.4%)
Filing Benefit Percentile
37.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 27.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner XIAO, YAN - Prosecution Strategy Guide

Executive Summary

Examiner XIAO, YAN works in Art Unit 1642 and has examined 817 patent applications in our dataset. With an allowance rate of 62.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner XIAO, YAN's allowance rate of 62.9% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by XIAO, YAN receive 1.76 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by XIAO, YAN is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +60.4% benefit to allowance rate for applications examined by XIAO, YAN. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.9% of applications are subsequently allowed. This success rate is in the 69% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 46.1% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 150.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 95.7% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.